Claris Lifesciences Ltd - IPO - Subscribe Says Nirmal Bang
Issue Price Rs. 278 - 293
Bidding Date 24 Nov’10 – 26 Nov’10
Outlook & Valuation
Nirmal Bang believe that the company has slected a niche opportunity for itself and has proven its credentials in it. It has 1100 global registrations and is one of the leading players in injectibles segment in emerging markets. It is trying to foray in regulated markets which hold 90% of global injectibke market. We believe that despite some hiccups (USFDA regulatory issue) Claris Lifesciences holds a promising future. Further deal with Pfizer boosts the confidence in company’s strong product pipeline. Given the high growth market, high margin-low competion scenario and company’s focus on profitbalilty than scale, Nirmal Bang is positive on the company’s outlook.
0 comments:
Post a Comment
All comments are moderated. Please post no spam